Drug intelligence / Profile preview

HLX92

Development stage: Preclinical
Lead developer: Healx
Modality: Small Molecules

Overview

HLX92 is an innovative small molecule drug developed by Shanghai Henlius Biotech. It is being investigated primarily for the treatment of primary sclerosing cholangitis and primary biliary cholangitis. HLX92 represents a new chemical entity in the pipeline of Henlius and is in the early stages of clinical evaluation. Specific details regarding its mechanism of action, molecular target(s), and further pharmacological profile have not been publicly disclosed as of the latest available information.

Beyond the preview

Go deeper on HLX92.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HLX92.

Explore the full profile